Plasma exosome‑encapsulated microRNA‑21 and microRNA‑92a are promising biomarkers for the prediction of peritoneal recurrence in patients with gastric cancer

作者：Naruyoshi Soeda, Hisae Iinuma, Yusuke Suzuki, Daisuke Tsukahara, Hironori Midorikawa, Yuichi Igarashi, Yoshimasa Kumata, Masahiro Horikawa, Takashi Kiyokawa, Takeo Fukagawa, Ryoji Fukushima · 发表于：Oncology Letters · 年份：2019 · DOI：10.3892/ol.2019.10807 · 被引用次数：33 · 研究领域：MicroRNA in disease regulation、Extracellular vesicles in disease、Circular RNAs in diseases

In patients with gastric cancer (GC), peritoneal recurrence is a common risk and associated with poor prognosis. A novel biomarker for the prediction of high-risk peritoneal recurrence in patients with GC is desirable. The present study investigated the effectiveness of exosome-encapsulated microRNAs (ex-miRNAs) as minimally invasive biomarkers in patients with GC that received curative surgery. Recurrence-specific ex-miRNAs were selected following comparison of miRNA microarray data from patients with TNM stage II GC with peritoneal recurrence (n=3) and without peritoneal recurrence following curative surgery (n=3), and three healthy volunteers. In this analysis, exosome-encapsulated miRNA-21 (ex-miR-21) and exosomal miR-92a (ex-miR-92a) exhibited the greatest alterations in expression patterns. Using plasma exosome samples collected from another 129 patients with stage II and III GC, the present study investigated the potential value of ex-miR-21 and ex-miR-92a as biomarkers. Ex-miRNA levels were measured using TaqMan miRNA assays. Ex-miR-21 levels were significantly higher and ex-miR-92a levels were significantly lower in samples from patients with GC compared with healthy controls. The overall survival (OS) and peritoneal recurrence-free survival (PRFS) were poorer in stage II and III patients with high ex-miR-21 levels than in patients with low miR-21 levels. OS and PRFS of stage II and III patients with low ex-miR92a levels were significantly worse than those with high ...